(Q39308116)

English

Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

10 September 2017

Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children (English)

1 reference

Europe PubMed Central

10 September 2017

1 reference

based on heuristic

inferred from title

influenza vaccine

1 reference

based on heuristic

inferred from title

5

object named as

Glenda Gray

1 reference

Europe PubMed Central

10 September 2017

1

object named as

Terry Nolan

1 reference

Europe PubMed Central

10 September 2017

2

object named as

Lulu Bravo

1 reference

Europe PubMed Central

10 September 2017

author name string

Ana Ceballos

3

1 reference

Europe PubMed Central

10 September 2017

Essack Mitha

4

1 reference

Europe PubMed Central

10 September 2017

Beatriz Quiambao

6

1 reference

Europe PubMed Central

10 September 2017

Sanjay S Patel

7

1 reference

Europe PubMed Central

10 September 2017

Svetlana Bizjajeva

8

1 reference

Europe PubMed Central

10 September 2017

Hans Bock

9

1 reference

Europe PubMed Central

10 September 2017

Nancy Nazaire-Bermal

10

1 reference

Europe PubMed Central

10 September 2017

Eduardo Forleo-Neto

11

1 reference

Europe PubMed Central

10 September 2017

Giovanni Della Cioppa

12

1 reference

Europe PubMed Central

10 September 2017

Vas Narasimhan

13

1 reference

Europe PubMed Central

10 September 2017

language of work or name

0 references

publication date

16 September 2014

1 reference

Europe PubMed Central

10 September 2017

1 reference

Europe PubMed Central

10 September 2017

32

1 reference

Europe PubMed Central

10 September 2017

46

1 reference

Europe PubMed Central

10 September 2017

6146-6156

1 reference

Europe PubMed Central

10 September 2017

The effect of mass influenza immunization in children on the morbidity of the unvaccinated elderly

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.068

7 January 2021

Influenza and the rates of hospitalization for respiratory disease among infants and young children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.068

7 January 2021

The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.068

7 January 2021

Socioeconomic impact of influenza on healthy children and their families

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.068

7 January 2021

Influenza-associated hospitalizations in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.068

7 January 2021

Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.068

7 January 2021

Vaccines for preventing influenza in healthy children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.068

7 January 2021

The feasibility of universal influenza vaccination for infants and toddlers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.068

7 January 2021

Epidemiology and pathogenesis of influenza

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.068

7 January 2021

Influenza vaccine--outmaneuvering antigenic shift and drift

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.068

7 January 2021

Influenza vaccine: the challenge of antigenic drift.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.068

7 January 2021

Influenza vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.068

7 January 2021

The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.068

7 January 2021

Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.068

7 January 2021

MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.068

7 January 2021

The mechanism of action of MF59 - an innately attractive adjuvant formulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.068

7 January 2021

MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.068

7 January 2021

Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.068

7 January 2021

Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.068

7 January 2021

Oil-in-water emulsion adjuvant with influenza vaccine in young children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.068

7 January 2021

Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.068

7 January 2021

Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.068

7 January 2021

Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.068

7 January 2021

Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.068

7 January 2021

Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.068

7 January 2021

Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.068

7 January 2021

The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.068

7 January 2021

Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.068

7 January 2021

Compliance with the recommendations for 2 doses of trivalent inactivated influenza vaccine in children less than 9 years of age receiving influenza vaccine for the first time: a Vaccine Safety Datalink study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.068

7 January 2021

Epidemiology, Complications, and Cost of Hospitalization in Children With Laboratory-Confirmed Influenza Infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.068

7 January 2021

Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: the importance of cross-protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.068

7 January 2021

The evolution of human influenza viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.068

7 January 2021

Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.068

7 January 2021

Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy: a six-month update

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.068

7 January 2021

Identifiers

10.1016/J.VACCINE.2014.08.068

1 reference

Europe PubMed Central

10 September 2017

1 reference

Europe PubMed Central

10 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39308116&oldid=1896609117"